Developing RNA vaccines to prevent cancer in high-risk individuals
CAP-IT Center for LNP RNA Immunoprevention
This study is testing new vaccines made from tiny particles to help people at higher risk of cancer, like those with Lynch syndrome or pre-cancerous lung issues, by boosting their immune system to prevent cancer from developing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10906209 on NIH RePORTER |
What this research studies
The CAP-IT Center for RNA Immunoprevention aims to create and validate innovative liponanoparticle RNA (LNP RNA) vaccines designed for individuals at increased risk of cancer. This research focuses on two main projects: one targeting Lynch syndrome, a genetic condition that heightens cancer risk, and another aimed at patients with pre-malignant lung lesions. Utilizing advanced technologies such as genomic analysis and immunopeptidomics, the research seeks to formulate vaccines that can effectively stimulate the immune system to prevent cancer development. Patients may benefit from cutting-edge preventive strategies tailored to their genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with Lynch syndrome or those diagnosed with pre-malignant lung nodules.
Not a fit: Patients without a genetic predisposition to cancer or those not at risk for lung adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that significantly reduce cancer risk in genetically predisposed individuals.
How similar studies have performed: Previous research has shown success with RNA vaccines in other contexts, particularly in COVID-19 prevention, indicating potential for similar breakthroughs in cancer prevention.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Lipkin, Steven M — Weill Medical Coll of Cornell Univ
- Study coordinator: Lipkin, Steven M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.